Table 2 Validation study patient characteristics
From: Altered Extracellular Vesicle MicroRNA Expression in Ischemic Stroke and Small Vessel Disease
Non-Stroke | Stroke | p (Fisher’s Test) | ||||
|---|---|---|---|---|---|---|
n | % | n | % | |||
Age and gender | N | 34 | – | 139 | – | NA |
Gender: male | 19 | 55.9 | 90 | 64.7 | 0.428 | |
Median age [IQR] | 63.5 [53.8–68.0] | – | 68.0 [57.0–76.0] | – | 0.055✞ | |
Risk factors for ischaemic stroke | Hypertension, % (n) | 13 | 38.2 | 57 | 41.0 | 0.847 |
Atrial fibrillation, % (n) | 3 | 8.8 | 27 | 19.4 | 0.206 | |
Diabetes (types 1 or 2), % (n) | 7 | 20.6 | 24 | 17.3 | 0.625 | |
Hyperlipidaemia, % (n) | 6 | 17.6 | 36 | 25.9 | 0.378 | |
Peripheral vascular disease, % (n) | 2 | 5.9 | 1 | 0.7 | 0.099 | |
Smoker, % (n) | 9 | 26.5 | 45 | 32.4 | 0.544 | |
Ex-smoker, % (n) | 11 | 32.4 | 23 | 16.5 | 0.053 | |
Previous stroke, % (n) | 5 | 14.7 | 19 | 13.7 | 1.000 | |
Family history, % (n) | 4 | 11.8 | 22 | 15.8 | 0.789 | |
Medication | Recombinant tissue plasminogen activator, % (n) | – | – | 39 | 28.1 | NA |
ACE inhibitor, % (n) | 8 | 23.5 | 32 | 23.0 | 1.000 | |
Alpha blocker, % (n) | 0 | 0.0 | 1 | 0.7 | 1.000 | |
Anticoagulant, % (n) | 2 | 5.9 | 8 | 5.8 | 1.000 | |
Antiplatelet, % (n) | 14 | 41.2 | 51 | 36.7 | 0.694 | |
ARB, % (n) | 1 | 2.9 | 9 | 6.5 | 0.689 | |
Beta blocker, % (n) | 10 | 29.4 | 35 | 25.2 | 0.664 | |
Blood pressure treatment, % (n) | 14 | 41.2 | 68 | 48.9 | 0.449 | |
CCB, % (n) | 5 | 14.7 | 25 | 18.0 | 0.803 | |
Loop diuretic, % (n) | 1 | 2.9 | 15 | 10.8 | 0.202 | |
Oral hypoglycaemic drugs, % (n) | 2 | 5.9 | 10 | 7.2 | 1.000 | |
Spironolactone, % (n) | 1 | 2.9 | 2 | 1.4 | 0.484 | |
Statin, % (n) | 16 | 47.1 | 60 | 43.2 | 0.704 | |
Thiazide, % (n) | 3 | 8.8 | 15 | 10.8 | 1.000 | |
Stroke status | Median baseline NIHSS [IQR] | 1 [0–3] | – | 4 [2–7] | – | < 0.0001♦ |